



21 December 2012

Results of Liver Fibrosis Project

Resonance Health has been undertaking a project with the aim to develop an MRI based technology to detect and measure liver fibrosis. The Company has conducted a number of studies which have shown some promising results. In 2011/12, the Company undertook an additional study in collaboration with the Austin Health liver unit in Victoria to explore this further. This study has now been completed.

The results have demonstrated an ability to detect liver fibrosis with MRI but unfortunately not with sufficient accuracy or sensitivity to be competitive with other products currently available. Whilst the results were not as positive as we had hoped, they provide a level of confidence to progress the project further and we are currently exploring alternative ways to analyse the image data that may enable improved detection of fibrosis that is competitive with other products.

The non-invasive measurement of liver fibrosis presents a significant opportunity for shareholders and the Company has not abandoned its aim to develop a solution for the non-invasive assessment of liver fibrosis.

By Order of the Board Resonance Health Limited

For further information please contact:

Resonance Health Liza Dunne Managing Director T: +61 8 9286 5300 E: <u>lizad@resonancehealth.com</u>

Naomi Haydari Company Secretary T: +61 8 9286 5300 E:<u>naomih@resonancehealth.com</u>

Resonance Health Ltd (ASX: RHT) (www.resonancehealth.com) is a medical device company providing imaging core laboratory services for the quantitative analysis of medical images, with a subspecialty in the liver. Resonance Health's patented FerriScan technology provides a safe and accurate alternative for measuring liver iron concentration, and research continues into the development of new technology for the accurate assessment of liver fat and liver fibrosis.